arrow
D

Derek J. Sloan

University of St Andrews
H指数:28
被引数:2,781

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

2026-08-140
PRE
Comparative assessment of host transcriptomic- and bacteriological-markers for monitoring treatment response among active tuberculosis patients: a longitudinal study

对宿主转录组学和细菌学标记物监测活动性结核病患者治疗反应的比较评估:一项纵向研究

2026-07-010
OA
Unpacking 'irrational' behaviours: Situating the antibiotic selling practices of drug sellers in East Africa

解构“非理性”行为:将东非药品销售者的抗生素销售实践置于情境中

2025-12-310
PRE
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial

Sutezolid与bedaquiline、delamanid和moxifloxacin联合治疗肺结核(PanACEA-SUDOCU-01):一项前瞻性、开放标签、随机、Ⅱb期剂量探索试验

2025-07-080
OAAI
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial

德尔帕索利德联合贝达喹啉、德拉马尼和莫西沙星治疗肺结核(PanACEA-DECODE-01):一项前瞻性、随机、开放标签、IIb期剂量探索试验

2025-07-080
OAAI
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Bedaquiline、Delamanid和Moxifloxacin与不同剂量的Sutezolid或Delpazolid联合或单独给药治疗药物敏感型结核病的 cardiac safety

2025-07-012
OA
Intersecting social and environmental determinants of multidrug-resistant urinary tract infections in East Africa beyond antibiotic use
2024-10-310
OAAI
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial

Bedaquiline-pretomanid-莫西沙星-吡嗪酰胺治疗药物敏感性和耐药性肺结核: 一项2c期,开放标签,多中心,部分随机对照试验

2024-09-016
OAAI
Predominance of multidrug-resistant bacteria causing urinary tract infections among symptomatic patients in East Africa: a call for action
2024-02-144
OAAI
Developing hands-on skills on tuberculosis sponsor responsibilities and clinical trial management for END-TB in Sub-Saharan
2023-12-170
OA